Zobrazeno 1 - 10
of 60
pro vyhledávání: '"Jean-Baptiste Briere"'
Autor:
Carlos Escobar Cervantes, Julio Martí-Almor, Alejandro Isidoro Pérez Cabeza, Kevin Bowrin, Aleix Llorac Moix, Mar Genís Gironès, David Gasche, Aurélie Millier, Jean Tardu, Mondher Toumi, Jean-Baptiste Briere
Publikováno v:
PLoS ONE, Vol 17, Iss 4, p e0266658 (2022)
AimsA Markov model was adapted to assess the real-world cost-effectiveness of rivaroxaban, dabigatran and apixaban. Each of these non-vitamin K antagonist oral anticoagulants was compared with vitamin K antagonist for stroke prevention in patients wi
Externí odkaz:
https://doaj.org/article/eb092c35bbd84ed6aa5885bab357e8be
Publikováno v:
Journal of Market Access & Health Policy, Vol 8, Iss 1 (2020)
Background Morbidity and mortality associated with non-valvular atrial fibrillation (NVAF) imposes a substantial economic burden on the UK healthcare system. Objectives An existing Markov model was adapted to assess the real-world cost-effectiveness
Externí odkaz:
https://doaj.org/article/5e95112410e74f1183cf795e93f044e3
Autor:
Kevin Bowrin, Jean-Baptiste Briere, Laurent Fauchier, Craig Coleman, Aurélie Millier, Mondher Toumi, Emilie Clay, Pierre Levy
Publikováno v:
PLoS ONE, Vol 15, Iss 1, p e0225301 (2020)
OBJECTIVE:The objective was to assess the real-world cost-effectiveness of rivaroxaban, versus vitamin K antagonists (VKAs), for stroke prevention in patients with atrial fibrillation (AF) from a French national health insurance perspective. METHODS:
Externí odkaz:
https://doaj.org/article/8513bdea822c4f258201969642d1647f
Autor:
Rupert Bauersachs, Olivia Wu, Jean-Baptiste Briere, Kevin Bowrin, Katarzyna Borkowska, Anna Jakubowska, Vanessa Taieb, Mondher Toumi, Maria Huelsebeck
Publikováno v:
Cardiovascular Therapeutics, Vol 2020 (2020)
Aims. Acetylsalicylic acid (ASA) is widely used for the prevention of atherothrombotic events in patients with chronic coronary artery disease (CAD) and peripheral artery disease (PAD), but the risk of vascular events remains high. We aimed at identi
Externí odkaz:
https://doaj.org/article/0e9c997f5b3640919ca68eb1c4468e08
Autor:
Craig I. Coleman, Jean-Baptiste Briere, Laurent Fauchier, Pierre Levy, Kevin Bowrin, Mondher Toumi, Aurélie Millier, Vanessa Taieb, Olivia Wu
Publikováno v:
Journal of Market Access & Health Policy, Vol 7, Iss 1 (2019)
Introduction: Numerous real-world studies have compared non-vitamin K antagonist oral anticoagulants (NOACs) with vitamin K antagonists (VKAs) in patients with non-valvular atrial fibrillation (NVAF). A meta-analysis was performed to synthesize the a
Externí odkaz:
https://doaj.org/article/2a8f043b0a824dbaa571cb468c552b94
Autor:
Pierre Levy, David M. Smadja, Julie Dorey, Mondher Toumi, Anna-Katharina Meinecke, Kevin Bowrin, Jean-Baptiste Briere
Publikováno v:
Journal of Market Access & Health Policy, Vol 7, Iss 1 (2019)
Background: Little is known about the costs associated with vitamin K antagonist (VKA) treatment in patients with non-valvular atrial fibrillation (NVAF) in France. Objectives: To evaluate monthly per-patient costs attributable to VKA treatment in NV
Externí odkaz:
https://doaj.org/article/36db1862bbdc4647977d929223085b73
Autor:
Laura Portas, Rupert Bauersachs, Kevin Bowrin, Jean-Baptiste Briere, Alexander Cohen, Maria Huelsebeck, Schuyler Jones, Jennifer K Quint
Publikováno v:
Vascular medicine (London, England). 27(5)
Background: Symptoms, severity, and acuteness of peripheral artery disease (PAD) are major determinants of severe limb symptoms, subsequent risk of cardiovascular events, and mortality. Lower-extremity revascularization (LER) is a key option to relie
Autor:
Kevin Bowrin, Aurélie Millier, Jean-Baptiste Briere, B. Verheggen, M. Coppens, S. Tempelaar, J. A. Spoorendonk
Publikováno v:
Journal of medical economics, 24(1), 1231-1239. Taylor and Francis Ltd.
Background: Patients with stable coronary artery disease (CAD) or peripheral artery disease (PAD) are at substantial risk of atherothrombotic events. The COMPASS trial showed that patients with stable CAD or PAD experienced significant benefits after
Publikováno v:
Journal of Medical Economics
Journal of Medical Economics, 2020, 23 (10), ⟨10.1080/13696998.2020.1792917⟩
Journal of Medical Economics, 2020, 23 (10), ⟨10.1080/13696998.2020.1792917⟩
Real-world evidence (RWE) provides external validity, supplementing and enhancing the randomized controlled trial data with valuable information on patient behaviors and outcomes, turning efficacy and safety results into real-world effectiveness and
Autor:
Janita Balradj, Kevin Bowrin, Marc Schindewolf, Maria Huelsebeck, Jean-Baptiste Briere, Jan Beyer-Westendorf
Publikováno v:
Angiology. 71:773-790
A systematic literature review was conducted to identify and summarize the clinical efficacy and safety of available antithrombotic therapies after peripheral endovascular or surgical revascularization in patients with peripheral artery disease (PAD)